Same Indication

Ipilimumab vs Palivizumab

Ipilimumab vs Palivizumab: Overview

This comparison examines the pharmacological differences between Ipilimumab and Palivizumab.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics

Half-life: Ipilimumab — 14.7 days.

Chemical Properties

Type: Ipilimumab — Antibody; Palivizumab — Antibody.